Welcome to our dedicated page for Globus Med news (Ticker: GMED), a resource for investors and traders seeking the latest updates and insights on Globus Med stock.
Globus Medical Inc (NYSE: GMED) drives innovation in musculoskeletal solutions and surgical robotics, delivering cutting-edge technologies for spinal and orthopedic procedures. This dedicated news hub provides investors and medical professionals with essential updates on the company's advancements in medical device innovation.
Key Resources: Access official press releases, financial announcements, and strategic partnership updates in one centralized location. Track developments in robotic-assisted surgery platforms, regulatory milestones for spinal implants, and clinical trial progressions shaping modern surgical care.
Content Focus: Our curated collection includes earnings reports, product launch details, FDA clearance announcements, and technology partnership disclosures. Stay informed about GMED's expanding portfolio of enabling technologies designed to enhance surgical precision and patient outcomes.
Stay Updated: Bookmark this page for real-time access to verified information about Globus Medical's market-moving developments. Regularly refreshed content ensures you maintain awareness of critical innovations in the evolving medical devices sector.
Globus Medical (NYSE:GMED) reported strong Q2 2025 financial results with worldwide net sales of $745.3 million, up 18.4% year-over-year. The company achieved GAAP net income of $202.8 million, a remarkable 538.7% increase, largely driven by a $110.6 million bargain purchase gain and a $34.8 million tax benefit.
Key highlights include U.S. net sales growth of 20.3% and international sales growth of 11.0%. The U.S. Spine business showed particular strength, growing 5.7% (7.4% day-adjusted). GAAP diluted EPS reached $1.49, while non-GAAP diluted EPS was $0.86, up 14.1% from Q2 2024.
The company reaffirmed its 2025 guidance, projecting revenue between $2.80-$2.90 billion and non-GAAP EPS of $3.00-$3.30.
Globus Medical (NYSE:GMED) announced significant leadership changes and preliminary Q2 2025 results. Keith Pfeil, former EVP, COO and CFO, has been appointed President and CEO, replacing Daniel Scavilla who resigned to pursue other opportunities. Additionally, Kyle Kline has been promoted to SVP and CFO.
The company reported preliminary Q2 2025 sales of $745.3 million, an 18.4% increase year-over-year. Base business sales, excluding Nevro Inc. acquisition, reached $650.8 million, growing 3.3% as reported and 4.8% on a day-adjusted basis. The US Spine business showed strong performance with 7.4% growth on a day-adjusted basis.
Globus Medical reaffirmed its full-year 2025 guidance with revenue expected between $2.80-$2.90 billion and non-GAAP EPS of $3.00-$3.30.
Globus Medical (NYSE:GMED), a leading musculoskeletal technology company, has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025, after market close.
The company will host a conference call at 4:30 p.m. Eastern Time to discuss the results with investors. Participants can join via webcast through the company's investor relations website or by telephone through pre-registration. The audio recording will be available after the call on the company's investor website.
Globus Medical (NYSE: GMED) has unveiled DuraPro™, a next-generation oscillating system with enhanced navigation capabilities through its Excelsius™ platform. The system aims to disrupt the $550 million high-speed drill market with innovative technology designed to protect delicate tissue during surgical procedures.
DuraPro™'s key features include anti-skiving pilot hole drilling, brush attachments for thorough discectomies, and seamless integration with ExcelsiusGPS™ and ExcelsiusHub™. The company also launched Verzera™, a navigated high-speed drill system, expanding their Power Portfolio of surgical solutions.
Globus Medical (NYSE: GMED) has announced a significant $500 million share repurchase program of its outstanding common stock. The company's management believes there is a disconnect between their intrinsic value and current market valuation due to recent share price volatility.
The program will be funded through cash reserves and has no time limit. The actual implementation will be at management's discretion, considering factors such as market price, business conditions, legal requirements, and alternative investment opportunities. The repurchases may be executed through private negotiations or open market transactions, including under Rule 10b5-1 and Rule 10b-18.
Globus Medical (NYSE:GMED), a leading musculoskeletal technology company, has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, after market close. The company will host a conference call at 4:30 p.m. Eastern Time to discuss the Q1 performance ending March 31, 2025.
Investors can access the earnings release through the company's investor relations website at www.investors.globusmedical.com. The conference call will be available via:
- Webcast: Through the Investors page on Globus Medical's website
- Telephone: Participants must pre-register using the provided link to receive dial-in details, passcode, and registrant ID
An audio archive of the call will be made available on the company's investor website following the event.
Globus Medical (NYSE: GMED) has completed its acquisition of Nevro Corp., a medical device company specializing in chronic pain treatment solutions. The strategic acquisition expands Globus Medical's presence in the musculoskeletal market, unlocking a $2.5 billion market opportunity in the neuromodulation space.
The deal aims to accelerate market penetration of Nevro's high-frequency technology for chronic pain treatment. Nevro's common stock has ceased trading on the NYSE as of April 3, 2025. Globus Medical plans to discuss the acquisition's benefits during its first quarter earnings conference in May.
Morgan Stanley & Co. and BofA Securities, Inc. served as financial advisors to Globus Medical and Nevro Corp., respectively.
Globus Medical (NYSE: GMED) has announced two significant product launches in its anterior spine portfolio: the COHERE™ ALIF Spacer and Modulus™ ALIF Blades.
The COHERE ALIF Spacer is the first Porous PEEK™ interbody spacer for anterior lumbar interbody fusion surgery, featuring proprietary porous surface technology for bone in-growth while maintaining imaging and mechanical properties. The technology combines PEEK's stiffness and radiolucency with osseointegration potential.
The Modulus ALIF Blades extend the Modulus ALIF Spacer portfolio by offering different fixation options and improved procedural efficiency through immediate anchoring blade fixation following interbody spacer placement. This innovation reduces the number of surgical steps and instruments needed, allowing for a more minimally invasive approach.
Globus Medical (NYSE: GMED) announced its participation in the 2025 American Academy of Orthopedic Surgeons (AAOS) Annual Meeting in San Diego from March 10-14, 2025. The company will showcase its comprehensive product portfolio at booth #2517, highlighting their latest innovation, the ExcelsiusFlex™ surgical robotic navigation system for Total Knee Arthroplasty (TKA).
The ExcelsiusFlex™ system combines accuracy, procedural flexibility, and surgeon-centric design, allowing customization of workflow. The company will also feature the PRECICE™ Intramedullary Limb Lengthening Portfolio, DuraPro™ Oscillating System, and Harvest™ SmartPrep™ 3 autologous biologic centrifuge platform.
Globus Medical will host a reception on March 12, 2025, from 5:30pm to 8:30pm at the San Diego Wine & Culinary Center, and a booth tour for analysts and investors from 1:00pm to 1:45pm the same day.
FAQ
What is the current stock price of Globus Med (GMED)?
What is the market cap of Globus Med (GMED)?
